Janux Therapeutics, Inc.
Key Metrics
Market Snapshot
About
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel T cell engager immunotherapies for the treatment of cancer. The company utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) platform to create conditionally activated bispecific antibodies that selectively target tumor cells while sparing healthy tissue. Janux is advancing multiple product candidates through clinical development targeting solid tumors and hematologic malignancies. The company aims to improve the therapeutic window and reduce systemic toxicity compared to traditional T cell engagers.